Background and Purpose-To evaluate the periprocedural outcome after carotid artery stenting with embolic brain protection (EBPϩ) versus without embolic brain protection (EBPϪ). Methods-We retrospectively reviewed data from a prospective nonrandomized database of 357 patients who underwent carotid artery stenting in the neuroradiology division of our institution from 1999 to 2009. One hundred five patients underwent angioplasty and stenting without distal protection, whereas 252 were treated with distal protection. Patients were analyzed according to their EBP status (ϩ or Ϫ) for the primary end points of perioperative stroke, death, or myocardial infarction. Results-Unprotected stenting was mostly performed in the early years of this study and this is reflected in significant baseline differences between the two groups. In our earlier experience, carotid artery stenting was used in patients with more significant comorbidities. Diabetes mellitus (Pϭ0.04), previous coronary artery disease (Pϭ0.02) and myocardial infarction (Pϭ0.04), and symptomatic lesion (Pϭ0.01) were significantly more common in the EBPϪ cohort. Despite these baseline differences, there were no significant differences in the primary end points (2% in the EBPϩ group and 4.8% in the EBPϪ, Pϭ0.15). The incidence of ipsilateral stroke in the EBPϪ and in the EBPϩ group was 3.8% versus 0.8%, respectively (Pϭ0.6). There were 2 perioperative deaths (1 in each group) and 4 myocardial infarctions (3 in the EBPϩ arm and 1 in the EBPϪ arm, all non-Q infarcts; Pϭnonsignificant). 
R ecent advances in endovascular techniques have added a feasible alternative to conventional surgical repair for the management of carotid diseases. Percutaneous carotid artery stenting (CAS) has the potential of being minimally invasive, less traumatic, and safer in patients with high surgical risk than carotid endarterectomy. [1] [2] [3] The main limitation of CAS is the risk of distal cerebral embolization caused by mobilization and migration of plaque fragments. Although cerebral protection devices have been developed and are widely used to prevent periprocedural cerebral embolization, their application may result in additional complications. 4 There are only 2 very small randomized studies that have evaluated the efficacy of such devices. 5, 6 These studies have suggested that protection devices may not be effective in reducing perioperative distal emboli and arguments have been formulated against their routine use. 7, 8 We reviewed our experience with Ͼ350 consecutive CASs and compared the incidence of perioperative complications in patients treated with and without distal protection.
Methods
We performed a retrospective review from a prospective database of consecutive CAS procedures done in the Neuroradiology Suite at the Mayo Clinic, Rochester, MN, from March 1999 to October 2009. Patient evaluation, intervention, and periprocedural evaluation were carried out by a team of neurologists, interventional neuroradiologists, neurosurgeons, and vascular surgeons. Patients with recurrent lesion after previous CAS were excluded. All CAS procedures were divided into 2 groups, protected embolic brain protection (EBPϩ) and nonprotected (EBPϪ) arms, on the basis of the use of the distal embolic brain protection device.
Patients were considered symptomatic if they had an ipsilateral amaurosis fugax or transient or persistent focal symptoms felt to be caused by cerebral ischemia. Data were collected regarding various risk factors, including preoperative renal insufficiency defined as a serum creatinine value Ͼ1.3 mg/dL; coronary artery disease defined on the basis of an abnormal stress test, previous myocardial infarction on electrocardiography, or a history of coronary artery revascularization (open or percutaneous); chronic obstructive pulmonary disease identified on pulmonary function studies or ongoing need for an inhaler or steroid treatment. Diabetes, hyperlipidemia, hypertension, and congestive heart failure were identified in patients undergoing active medical or dietary treatment.
Significant stenosis requiring treatment was considered a stenotic lesion Ͼ50% in symptomatic patients or Ͼ80% in asymptomatic patients. Patient characteristics are summarized in Table 1 .
Primary and Secondary End Points
The primary study end points were periprocedural stroke, myocardial infarction, and death; secondary end points included acute carotid thrombosis, major renal, pulmonary, or cardiac complications, and intensive care unit and hospital length of stay. Stroke was diagnosed on the basis of new neurological deficit. Renal function impairment after stenting was defined as a serum creatinine concentration Ͼ1.3 mg/dL in patients with previous normal renal function or an increase Ͼ0.2 mg/dL in patients with preprocedural renal insufficiency, measured during the hospital period. Cardiac complications, which included myocardial infarction (MI) and arrhythmias, were defined by clinical symptoms associated with elevation of biochemical markers and electrocardiography findings. Arrhythmia was defined as pulse rate Ͻ60 beats/min or Ͼ100 beats/min or persistent rhythm alteration on telemetry during the intensive care unit stay. Transient arrhythmias occurring during the procedure were not considered. Pulmonary complications were defined as ventilator dependence for Ͼ6 hours after the procedure, need of postoperative intubation, clinical data or culture confirmation of pneumonia, or the need of tracheostomy. Abnormal SpO 2 was defined as a value of oxygen saturation Ͻ90% measured with pulse oximeter.
Technique
Patients were premedicated with 75 mg clopidogrel per day and 325 mg aspirin per day starting 5 days before the procedure or given a loading dose immediately before the procedure and continued for a minimum of 4 weeks. The procedure was performed under local anesthesia and this permitted careful clinical assessment during each step. However, general anesthesia was preferred in a few cases of uncooperative patients or when difficult and tortuous proximal anatomy made catheterization challenging. Brachiocephalic angiography with intracranial views always preceded stenting. The percentage stenosis was based on the angiographic findings and calculated using North American Symptomatic Carotid Endarterectomy Trial (NASCET) method in all cases. 9 When the distal protection technique was performed, filter or, rarely, balloon devices were used. The endovascular procedure was conducted under full heparinization with the goal of maintaining the activated clotting time approximately 2 times the baseline value. All patients were premedicated with atropine (1 to 2 mg) before angioplasty to reduce the incidence of bradycardia. CAS was achieved by a standard technique according to which a self-expanding stent placement was usually preceded by predilatation of the lesion. Stent overdilatation was avoided. Poststenting dilatation was reserved only for cases in which hemodynamically significant stenosis persisted. A final ipsilateral intracranial angiogram was obtained routinely at the end of the procedure to rule out distal vessel embolization. After the intervention, the activated clotting time was rechecked and heparinization was reversed with Protamine. Access hemostasis was achieved by manual compression in the majority of patients and with closure devices in a few. After the procedure, all patients were transferred to the intensive care unit for continuous hemodynamic and frequent neurological monitoring overnight.
Data Analysis
Statistical analysis was performed using JMP 8.0 (SAS Institute Inc) software. Proportions were compared by using 2 or Fisher exact tests, as appropriate. Logistic regression models were used to analyze only the association with stroke outcome variables (the rates of death, MI, and restenosis were too low to allow any valid analysis of predictors of these outcomes). Univariate logistic regression models were fit for each variable. Results are reported with OR, 95% CI for PR, and probability value. Multivariate analysis was not pursued for any of the end points because of low event rates. PϽ0.05 was considered significant for all analyses.
Results

Patient Characteristics
Three hundred fifty-seven CASs were included in this study. Symptomatic lesions were significantly more common in the EBPϪ group (60% versus 42%, Pϭ0.01) as well as a history of diabetes mellitus (Pϭ0.04) and previous MI (Pϭ0.04), reflecting use of CAS only in very high-risk populations in the early part of the experience. Demographic and clinical data are summarized in Table 1 .
Intraoperative Data
Distal balloon occlusion was used for distal protection in 24 cases, whereas in 228 cases, distal filters were used. The angiographic characteristics of the patients included in this series are summarized in Table 2 . In each group, patients were divided into 4 subsets according to the timing of percutaneous transluminal angioplasty. In the EBPϪ arm, postdilatation alone and primary stenting were performed significantly more frequent than in the EBPϩ arm (Pϭ0.01 and PϽ0.001, respectively) reflecting different operators' preference. The prestenting dilatation and pre-and poststenting dilatations were used with similar frequency in the 2 groups. The percentage of residual stenosis after the procedure (divided into 3 levels, 1 Ͻ20%; 2ϭ20% to 40%; 3 Ͼ40%) was not different between the 2 groups.
Morbidity and Mortality
Periprocedural ipsilateral stroke, MI, and mortality are presented in Tables 3 and 4 . The overall stroke rate was 1.7% (patients with symptomatic carotid stenosis, 2.4%; patients with asymptomatic carotid stenosis, 1.1%). Two of the 6 strokes were related to acute in-stent thrombosis, and the others were considered to be the result of embolism. Among EPDϩ indicates embolic protection device used; EPDϪ, embolic protection device not used; CHD, congestive heart failure; CAD, coronary artery disease; MI, myocardial infarction; COPD, chronic obstructive pulmonary disease; CRI, chronic renal insufficiency; PAD, peripheral artery disease.
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patients who experienced embolic stroke, 3 were treated with pre-(before stenting) dilatation alone (1 in protected CAS and 2 in nonprotected CAS) and 1 underwent postdilatation alone (nonprotected group) and the difference was not significant (Pϭ0.09). Stroke rate was higher in patients with symptomatic carotid disease in both groups (EBPϩ: symptomatic, 1.0%; asymptomatic, 0.7%; EBPϪ: symptomatic, 4.75%; asymptomatic, 2.4%), but these differences were again not statistically significant.
Overall mortality was 0.6% (symptomatic, 0.6%; asymptomatic, 0.5%). The difference in mortality between the EBPϩ group (0.4%) and EBPϪ group (0.95%) was not significant. The low event rate (nϭ2) did not allow further statistical analysis of predictors of postoperative death. Four myocardial events were observed (all non-Q wave). Three (1.2%) occurred in the EBPϩ and 1 (1.0%) in the EBPϪ group (Pϭnonsignificant).
When only patients treated with distal filter devices were considered (nϭ228), the stroke rate was 0.8% versus 3.8% in the nonprotected CAS group (Pϭ0.08). There were 3 MIs (1 less than in all protected CASs) and the overall stroke/ death/MI was 1.7% (2% in all protected CASs). When compared with the nonprotected (EPDϪ) group, the primary combined end point of stroke/death/MI was not statistically significant (Pϭ0.15). Temporary or permanent increases of serum creatinine concentration were seen in 6 patients in the EBPϩ arm and in 9 patients in the EBPϪ arm (Pϭnonsignificant). The incidence of restenosis after the procedure was mildly higher in the EBPϪ than in the EBPϩ (Pϭ0.054). Hospital length of stay was 2.1Ϯ2.5 days and 2.3Ϯ2.6 days (Pϭnonsignificant) in protected and unprotected arms, respectively. Finally, intensive care unit stay was longer in the unprotected group than in the EBPϩ group (Table 5 
Clinical Predictors
Age Ն70 years was significantly associated with 2.1-fold increase in stroke when considering all cases combined. We found no other variable to be associated with the risk of stroke.
Discussion
Distal protection devices have become "standard of care" during angioplasty and stenting for carotid artery stenosis. These devices "… appear seductively simple, elegant, and beneficial to both physician and patients," 10 yet there is no strong evidence that distal protection is effective in reducing the incidence of thromboembolic complications during CAS. 6, [11] [12] [13] [14] [15] [16] [17] We found no significant differences in the inci- dence of perioperative stroke, MI, and death rates between patients treated with or without distal protection. There was a slightly higher incidence of perioperative strokes in the nonprotected group, which did not reach statistical significance. The EBPϪ group reflected mostly our early experience (including the very first cases) with devices not specifically designed for use in the carotid system and less operator experience (1999 to 2003; Figure) . Moreover, symptomatic status (a known risk factor for periprocedural ischemic complications 18, 19 ) was significantly more common in the EBPϪ group (60% versus 42%, Pϭ0.01). During CAS, there is a real risk of dislodging microemboli after each stage of the procedure (crossing the lesion, prestent angioplasty, stenting, and poststent angioplasty). 20 Protection devices have been designed in an attempt to reduce the risk of distal microemboli. The concept is theoretically very appealing, but in practice, there are several factors limiting the true efficacy of distal protection. The first 1 is the need to cross the lesion before protection is achieved. The second drawback is related to the stiffness of these devices, which makes navigation through the stenosis challenging, especially in the presence of proximal and/or distal (to the stenosis) tortuosity (very common in patients with atherosclerotic disease). The filter "recatch" phase is another potential generator of distal emboli. 21 Despite adequate restoration of carotid lumen after CAS, it is possible that the "bulky" protection device may dislodge plaque debris protruding through the stent struts during the retrieval phase.
In the absence of Class I evidence, indirect observational studies-often with historical controls-initially supported the use and suggested potential efficacy of distal protection during CAS. 12 17 the rate of stroke in the group treated with protection devices was higher (5.1%) than in the group in which no protection was used (2.4%). In this same study, the rate of MRI diffusion-weighted abnormalities after CAS was also higher in the protected group. Finally, Tietke et al 24 retrospectively analyzed 358 unprotected CAS, reporting a very low (2%) rate of periprocedural stroke suggesting that "safe" CAS can be performed without such adjuncts. Our observation is in line with the conclusions of these studies questioning the efficacy of these devices.
To avoid some of the problems encountered with "filtertype" protection devices, other concepts have been proposed to reduce the incidence of distal emboli. Flow reversal can be achieved with a triple lumen-guiding balloon catheter with an additional distal occlusion balloon. Flow is arrested through the common carotid artery by inflating the balloon catheter and reversed by occluding the external carotid with the distal balloon. The reversed flow is directed through the guiding catheter, which is externally connected to a blood-filtered femoral vein line. 25 Although appealing, superiority of flowreversal devices over "filter types" has not been tested in a randomized study.
Among patients with asymptomatic carotid stenosis, the risk of stroke or death was 1.3% with EBP and 2.4% without EBP, which could be higher than with modern intensive medical therapy alone. However, our asymptomatic patients undergoing the intervention were a selected population and these often had progression of plaques despite aggressive medical treatment. Whether stenting or endarterectomy can be justified for patients with asymptomatic stenosis is currently a matter of debate. 26, 27 Future studies of endarterectomy or stenting in asymptomatic stenosis should have a medical arm.
Our study has several limitations. Nonprotected stenting was mainly performed in the first phase of the institutional experience with operators having different backgrounds, techniques, and levels of experience. However, in theory, these differences should have been an advantage for the protected group because distal protection was used almost routinely in the most recent part of the experience when operators had already acquired greater expertise in CAS and patients undergoing CAS were not as complicated (in terms of significant comorbidities) as was commonly the case in the early years of CAS. Moreover, this is the largest single-center study comparing protected and unprotected CAS to our knowledge with precise criteria of data collection and independent vascular neurologist assessment of most patients, resulting in high-quality and a large spectrum of information for each patient.
Conclusions
In line with recent experience, our observation questions the real efficacy of routine distal protection during CAS. It is likely that improved technology and the design of refined distal protection devices in the near future may overcome some of the current limitations. Given the large number of CAS procedures already being performed in North America and the likely increase in the use of this revascularization technique after the publication of the Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST) results, these observations call for a well-designed multicenter study to determine the value of distal protection in CAS.
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